Myhibbin (Mycophenolate Mofetil) Patent Expiration, LOE Window & CMS Spending

Myhibbin (Mycophenolate Mofetil) by Azurity: FDA Orange Book LOE 2039-08-16, 26 AB generics, $29K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN216482 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-08-16
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors26
2024 CMS Total Public Spend$29K
2024 Medicare Part D Spend$13K
2024 Medicaid Spend$16K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel